reports
BlackLine Announces Participation in Upcoming Investor Conference
BlackLine Announces Participation in Upcoming Investor Conference LOS ANGELES, Aug. 20, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL) today announced that BlackLine’s management team will participate in the following upcoming investor conference: Citi’s 2025 Global TMT ConferenceWednesday, September 3, 2025Presentation time: 10:10 AM ETLocation: New York, NY The presentation webcast will be accessible on BlackLine’s investor relations website at . About BlackLine (Nasdaq: BL), the future-ready platform for the Office of the CFO, drives digital finance transformation by empowering organizat...
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025. Ben has been with Myriad for more than 13 years, joining the Company in December 2011 as assistant controller and advancing through leadership roles including vice president, corporate controller; senior vice president, accounting; and since 2022, chief financial officer, operations. Scot...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Rea...
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened—primarily...
Blackline Inc: 1 director
A director at Blackline Inc bought 10,000 shares at 48.600USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
- Jonathan Moreland
TNDM TANDEM DIABETES CARE INC
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
GOGO GOGO INC.
CNC CENTENE CORPORATION
CHD CHURCH & DWIGHT CO. INC.
ASA ASA
SAFT SAFETY INSURANCE GROUP INC.
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
BL BLACKLINE INC.
ICHR ICHOR HOLDINGS LTD.
SONO SONOS
ESTA ESTABLISHMENT LABS HOLDINGS
PINE ALPINE INCOME PROPERTY TRUST
FOUR SHIFT4 PAYMENTS
DLHC INC.
ENVX DALEIGH HOLDINGS CORP
PTLO ENOVIX CORP
BRCC PORTILLOS INC
CSR BRC INC
SMRT INVESTORS REAL ESTATE TRUST
LNW SMARTRENT INC
BOOM LIGHT & WONDER INC.
DYNAMIC MATERIALS CORPORATION
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises ...
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum Highlights Second quarter 2025 revenue of $213.1 million increased by 1% year-over-year. Excluding previously discussed headwinds1 of $9.5 million, revenue increased 5% year-over-year.Second quarter 2025 hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively, as MyRisk with RiskScore testing volume in oncology grew 14% year-over-year. Second quarter 2025 gross margin of 71.2% increased over 160 basis points year-ov...
Myriad Genetics Announces New $200 Million Credit Facility
Myriad Genetics Announces New $200 Million Credit Facility SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year senior secured term loan credit facility providing up to $200 million of capital from OrbiMed, a leading global healthcare investment firm. The facility includes $125 million of funded capital with an option to borrow up to an additional $75 million until June 30, 2027. This facility matures on July 31, 2030, and bears interest at a rate based upon the one-mo...
Myriad Genetics to Release Second Quarter 2025 Financial Results on Au...
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025 SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the second quarter 2025. A live webcast of the conference call can be ...
BlackLine Announces Date for Second Quarter 2025 Earnings Release and ...
BlackLine Announces Date for Second Quarter 2025 Earnings Release and Conference Call LOS ANGELES, July 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL) announced today that it will release financial results for the second quarter ended June 30, 2025 after market close on Tuesday, August 5, 2025 followed by a conference call hosted by management at 2:00 p.m. PT / 5:00 p.m. ET. A live webcast and replay will be accessible on BlackLine’s investor relations website at . To access the conference call by phone, please register , and dial-in details will be provided. To avoid delays, we encourage par...
Myriad Genetics Earns 2025 Great Place To Work Certification™
Myriad Genetics Earns 2025 Great Place To Work Certification™ SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work – 30 percentage points higher than the average U.S. company. “Our focus on inclusivity and caring makes this a great p...
BlackLine’s Signature Finance Transformation Event Returns to London a...
BlackLine’s Signature Finance Transformation Event Returns to London and Debuts in Paris LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- BlackLine is expanding the reach of its flagship finance transformation event, BeyondTheBlack, with two key events in Europe this June. BeyondTheBlack will return to London on June 17, followed by its debut in Paris on June 19, marking the first time the event has been held in France. Each event brings together finance and accounting leaders across industries to explore how world-class companies are achieving smarter, faster, and more scalable financial opera...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prena...
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will simultaneously delive...
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of ...
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via ultra-sensitive MRD SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the Na...
BlackLine Announces Participation in Upcoming Investor Conferences
BlackLine Announces Participation in Upcoming Investor Conferences LOS ANGELES, May 27, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL) today announced that BlackLine’s management team will participate in the following upcoming investor conferences: Baird 2025 Global Consumer, Technology & Services ConferenceTuesday, June 3, 2025Presentation time: 2:00 PM ETLocation: New York, NY William Blair 45th Annual Growth Stock ConferenceWednesday, June 4, 2025Presentation time: 10:40 AM CTLocation: Chicago, IL BMO Virtual Software ConferenceTuesday, June 10, 2025Presentation time: 12:15 PM ETLocation: ...
Myriad Genetics Highlights New Research Advancements and Oncology Inno...
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new research studies at the 2025 ASCO Annual Meeting, including MRD clinical outcome data from the . Myriad will also highlight how its comprehensive portfolio of genetic and tum...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healt...
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences Correction: Time of BofA Conference SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the following investor healthcare conferences: The BofA Securities 2025 Health Care Conference – fireside chat at 6:00 pm ET (updated) on Wednesday, May 14, 2025.Goldman Sachs 46th Annual Global Healthcare Conference – fireside chat at 2:00 pm ET on Wednesday, June 11, 2025. Liv...
BlackLine Expands Agentic AI Capabilities to Accelerate Future-Ready F...
BlackLine Expands Agentic AI Capabilities to Accelerate Future-Ready Financial Operations With trusted, user-controlled AI embedded across its platform, BlackLine empowers the Office of the CFO to streamline operations, unlock insights, and confidently move toward autonomous finance LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL) today announced the continued expansion of its artificial intelligence (AI) capabilities, including new agents, delivering on its vision to power future-ready financial operations. With AI now embedded across every major financial workflow—from rec...
Myriad Genetics Announces RiskScore Study Published in JCO Precision O...
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients’ individual risk. RiskScore, Myriad’s clinically validated breast cancer risk assessment tool integ...
BlackLine Announces First Quarter Financial Results
BlackLine Announces First Quarter Financial Results LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), today announced financial results for the first quarter ended March 31, 2025. “BlackLine’s first quarter delivered solid results with bookings exceeding expectations, driven by improved execution along with continued margin expansion,” said Owen Ryan, Co-CEO of BlackLine. “Our key strategic initiatives continue to advance steadily: Studio360 adoption is growing, our new pricing strategy is gaining traction, our industry-specific approach is building momentum, and our public s...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates ...
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, ben...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.